Vera Therapeutics, Inc. (VERA): Total Liabilities
$130.21M
As of 2025-12-31
$125.23M
As of 2026-06-30
+33.7%
3-year compound annual growth
+97.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $130.21M | +65.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $78.53M | +6.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $73.86M | +35.5% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $54.53M | +285.2% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $14.16M | +227.2% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $4.33M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $130.21M | +65.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $92.32M | +97.2% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $170.26M | -1.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $76.67M | +173.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
Compare VERA, KURA, SDGR, SMMT side by side · Screen every company in Pharmaceutical Preparations ↗